CareDx (NASDAQ: CDNA) and Digiliti Money (NASDAQ:DGLT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.
Valuation & Earnings
This table compares CareDx and Digiliti Money’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|CareDx||$45.65 million||0.73||-$11.23 million||($1.44)||-1.08|
|Digiliti Money||$9.03 million||0.44||-$6.89 million||N/A||N/A|
Digiliti Money has higher revenue, but lower earnings than CareDx.
This table compares CareDx and Digiliti Money’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
34.9% of CareDx shares are owned by institutional investors. Comparatively, 4.8% of Digiliti Money shares are owned by institutional investors. 5.4% of CareDx shares are owned by insiders. Comparatively, 50.9% of Digiliti Money shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a summary of current recommendations for CareDx and Digiliti Money, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Digiliti Money has a consensus price target of $6.00, suggesting a potential upside of 1,391.05%. Given Digiliti Money’s higher probable upside, analysts plainly believe Digiliti Money is more favorable than CareDx.
CareDx Company Profile
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
Digiliti Money Company Profile
Digiliti Money Group, Inc., formerly Digiliti Money, Inc., is a technology solutions and services provider to the financial services industry. The Company’s solutions and services enable its clients, such as banks, credit unions and alternative financial services providers (AFS) to offer their customers remote deposit capture (RDC) and prepaid mobile money technologies and related services. It offers RDC products for businesses and consumers; mobile money management products for consumers, and training and support services for its financial services industry customers. The RDC products are offered to banks and credit unions in the United States, Canada and Latin America. Its mobile money management products are offered to traditional financial institutions (FIs), as well as AFS in the United States, Canada and Latin America. These FIs and AFS providers include banks, credit unions, prepaid card issuers, check cashers and payday lenders.
What are top analysts saying about CareDx Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CareDx Inc. and related companies.